Literature DB >> 17987324

[Federal Court of Justice verdict on the Racz catheter].

R Jungbecker1, M Zenz.   

Abstract

New ground operations involve the risk of liability for various reasons, and this applies both to the treatment and to the conduct of the interview to give the patient the necessary information. When the appropriate standards are observed, however, both sources of error can be avoided. Basically, methods that break new ground are allowed and come under the heading of doctors' freedom to choose the therapy. It is only when the new method involves a higher risk than the conventional method that there must be specific reasons (e.g. a better prognosis) justifying the novel method. If the side-effects of a method are not yet adequately known, however, as for the minimally invasive epidural catheter technique (Racz method) used in the case considered by the Federal Court of Justice, the attendant doctor is required to perform constant, and if necessary immediate, monitoring examinations to ensure that such side effects are not present or to react without delay if any do occur. The carefulness standard of the "prudent doctor" must be applied in these circumstances. It is also important that the patient is informed on the novel nature of the procedure (and the risks inherent in it, which may not yet be well known).

Entities:  

Mesh:

Year:  2007        PMID: 17987324     DOI: 10.1007/s00482-007-0597-5

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  11 in total

Review 1.  Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment.

Authors:  A Hróbjartsson; P C Gøtzsche
Journal:  N Engl J Med       Date:  2001-05-24       Impact factor: 91.245

Review 2.  [Risks and complications of epidural neurolysis -- a review with case report].

Authors:  K J Wagner; T Sprenger; C Pecho; E F Kochs; T R Tölle; A Berthele; L Gerdesmeyer
Journal:  Anasthesiol Intensivmed Notfallmed Schmerzther       Date:  2006-04       Impact factor: 0.698

Review 3.  Placebos and painkillers: is mind as real as matter?

Authors:  Luana Colloca; Fabrizio Benedetti
Journal:  Nat Rev Neurosci       Date:  2005-07       Impact factor: 34.870

4.  [Severe complications due to a dubious therapy].

Authors:  G Sprotte; M K Herbert
Journal:  Anasthesiol Intensivmed Notfallmed Schmerzther       Date:  2006-04       Impact factor: 0.698

5.  What do you expect from this treatment? Changing our mind about clinical trials.

Authors:  Fabrizio Benedetti
Journal:  Pain       Date:  2007-02-09       Impact factor: 6.961

6.  The lumbar disc herniation. A computer-aided analysis of 2,504 operations.

Authors:  E V Spangfort
Journal:  Acta Orthop Scand Suppl       Date:  1972

7.  Intractable pain therapy using a new epidural catheter.

Authors:  G B Racz; M Sabonghy; J Gintautas; W M Kline
Journal:  JAMA       Date:  1982-08-06       Impact factor: 56.272

8.  Treatment efficacy is not an index of pain intensity.

Authors:  C Mamie; A Morabia; M Bernstein; C E Klopfenstein; A Forster
Journal:  Can J Anaesth       Date:  2000-12       Impact factor: 5.063

9.  Percutaneous epidural neuroplasty: prospective evaluation of 0.9% NaCl versus 10% NaCl with or without hyaluronidase.

Authors:  J E Heavner; G B Racz; P Raj
Journal:  Reg Anesth Pain Med       Date:  1999 May-Jun       Impact factor: 6.288

10.  Loss of expectation-related mechanisms in Alzheimer's disease makes analgesic therapies less effective.

Authors:  Fabrizio Benedetti; Claudia Arduino; Sara Costa; Sergio Vighetti; Luisella Tarenzi; Innocenzo Rainero; Giovanni Asteggiano
Journal:  Pain       Date:  2006-02-10       Impact factor: 6.961

View more
  2 in total

Review 1.  [Limits of pain treatment: medical and judicial aspects].

Authors:  M Zenz; R Rissing-van Saan
Journal:  Schmerz       Date:  2011-08       Impact factor: 1.107

Review 2.  [Concepts of in-patient gradual diagnostics for patients with lumbar back-pain].

Authors:  R Kayser; K Mahlfeld; C E Heyde
Journal:  Orthopade       Date:  2008-04       Impact factor: 1.087

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.